Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alvotech PIPE Financing Round Overshoots By $21m

Icelandic Firm Now Anticipates $475m Gross Proceeds Via SPAC Merger

Executive Summary

“Testament to the strong interest we have received from long-term investors as we continue our business combination with Oaktree II,” Alvotech is now set to raise in excess of $175m from an upsized PIPE financing round, representing $21m of additional commitments.

You may also be interested in...



Alvotech Acquires Reykjavik Manufacturing Facility Amid $136m Financing Boost

Months after it become a public company, Alvotech has once again turned to the debt/equity markets to provide financial firepower for its pipeline of biosimilar candidates.

Alvotech Chases Debt Backup As Shareholders Redeem From The Pot

Alvotech is furthering efforts to have a debt facility in place worth up to $125m as it kicks off life as a public company, amid challenging global market conditions.

Icelandic Exchange Approves Alvotech As Its Shares Trade In NY

Alvotech is celebrating an “historic milestone” as it became a publicly listed company in New York, with its shares set to also trade in its domestic Iceland next week.

Related Content

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel